In July 2024, Flo Health achieved what no purely digital women’s health company in Europe had accomplished before: a valuation exceeding $1 billion. The milestone came with a $200 million Series C led by General Atlantic—one of the world’s leading growth equity firms.

The femtech company’s rise reflects broader momentum in women’s health investment. Investors have poured nearly $5 billion into the sector over three years—a 60% increase from the prior period. But achieving unicorn status required more than favorable market conditions. It required a product that 420 million people wanted to use.

General Atlantic’s investment thesis centered on category leadership and innovation potential. The company’s recent expansion into perimenopause tracking demonstrates continued product development addressing underserved life stages. The launch of new health features keeps users engaged across decades of their health journey.

Strategic infrastructure investments position the company for the next growth phase. Having achieved FDA readiness without slowing innovation, the platform can pursue clinical-grade features that competitors without regulatory infrastructure cannot.

With development hubs in London, Amsterdam, and Vilnius, the European roots remain strong. But the ambition is global—serving women throughout their entire health journey, everywhere in the world.